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Using a simple metagenomic approach, we identiﬁ  ed a 
divergent human parechovirus (HPeV) in the stool of a child 
in Pakistan. Genomic characterization showed this virus 
was distinct enough from reported HPeV types to qualify as 
candidate prototype for the seventh HPeV type.
H
uman parechoviruses (HPeVs) belong to the recently 
identiﬁ  ed genus Parechovirus of the family Picorna-
viridae. Serologic and molecular studies show that HPeV 
comprises 6 neutralization serotypes or corresponding types 
based on capsid protein similarities, HPeV1–6. HPeV1 
and HPeV2, originally known as enterovirus echoviruses 
22 and 23, were isolated in 1956 (1). Because echoviruses 
22 and 23 had serologic, molecular, and biologic proper-
ties highly distinct from other enteroviruses, they were re-
classiﬁ  ed in 1999 as members of the genus Parechovirus 
(2). The other 4 parechovirus types were identiﬁ  ed more 
recently from young children with clinical manifestations 
similar to those caused by human enteroviruses: HPeV3 in 
2002 (3), HPeV4 in 2005 (4), and HPeV5 (5) and HPeV6 
(6) in 2006. HPeV infections occur commonly in the gen-
eral population and mostly cause mild gastrointestinal and 
respiratory symptoms in young children (7). More severe 
consequences also have been ascribed to HPeV infections, 
including acute ﬂ  accid paralysis (AFP) (3), encephalitis 
(8), aseptic meningitis (9), myocarditis (10), neonatal sep-
sis (11), and Reye syndrome (6),
Nonpolio AFP may be caused by many viruses, in-
cluding nonpolio enteroviruses, human adenoviruses, her-
pes simplex virus, Epstein-Barr virus, and West Nile virus 
(12). HPeV1 was associated with an AFP outbreak in Ja-
maica in 1986. In 2 of 3 AFP patients with HPeV1 detected 
in stool samples, antibody titer also increased signiﬁ  cantly 
(13). HPeV6 was isolated from the stool specimen of an 
AFP patient in Japan in 2001 (6). HPeV3 has not been 
reported from AFP cases but was identiﬁ  ed in 1 transient 
paralysis case and believed to cause serious central ner-
vous system symptoms more frequently than HPeV1 (3,7). 
HPeV types 2, 4, and 5 have been less often observed in 
clinical studies.
Using sequence-independent PCR ampliﬁ  cation and 
sequence similarity searches, we recently investigated vi-
rus sequences in stool samples from children in Pakistan 
who had nonpolio AFP and from healthy children who 
had close contacts with persons who had AFP. Sequences 
of human parechoviruses were identiﬁ  ed in samples from 
6 of 65 persons. Analysis showed 5 HPeV infections in 56 
samples from persons who had nonpolio AFP, 1 HPeV1, 1 
HPeV5, and 2 HPeV6; in 1 sample, HPeV type could not 
be determined because the sequenced fragment was lo-
cated in a phylogenetically uninformative region. A high-
ly divergent HPeV type also was identiﬁ  ed in 1 contact 
sample, and the full genome of this virus was sequenced. 
Phylogenetic analysis indicated that this virus, designated 
PAK5045, has the genetic characteristics expected of a 
new HPeV type.
The Study
HPeV PAK5045 was found in 1 stool sample from a 
healthy 2-year-old boy who had close contact with a person 
who had nonpolio AFP, using a previously described meth-
od applied here to stool samples (14). Brieﬂ  y, virus nucleic 
acids were puriﬁ  ed from stool samples, randomly ampliﬁ  ed 
by reverse transcription (RT)–PCR using 3′ randomized 
RT and PCR primers, subcloned, and sequenced. HPeV 
sequences were abundant in 1 sample with 24/48 plas-
mid subclones identiﬁ  ed as PAK5045. Assembly of these 
HPeV sequences produced 5 fragments covering ≈75% of 
the genome. Speciﬁ  c PCR primers were used to link these 
genome fragments, and rapid ampliﬁ  cation of cDNA ends 
was carried out to acquire the 5′ and 3′ ends.
The nucleotide sequence of PAK5045 virus was 7,127 
nt, excluding a poly (A) tail. PAK5045 contained a partial 
5′ untranslated region (UTR) of 511 nt, an open reading 
frame (ORF) encoding a putative polyprotein precursor 
of 2,175 aa, and a 3′ UTR of 88 nt. The nucleotide se-
quence of PAK5045 was generated with at least 2× cov-
erage except for the 5′ UTR. The full-length sequence of 
PAK5045 has been deposited in GenBank under accession 
no. EU556224.
The polyprotein of PAK5045 comprised capsid proteins 
VP0 (289 aa), VP3 (254 aa), and VP1 (226 aa) and nonstruc-
tural proteins 2A (149 aa), 2B (122 aa), 2C (329 aa), 3A (117 
aa), 3B (20 aa), 3C (200 aa), and 3D (469 aa). Comparison of 
the complete ORF of PAK5045 with the 6 HPeV prototypes 
showed it was closely related to HPeVs and had amino acid 
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identity of 84.8%–89.1% and nucleotide identity of 75.6%–
80.8% (Table 1). Of the 6 known HPeV types, the intertype 
amino acid identities ranged from 84.9% to 91.1%, and the 
intertype nucleotide identities of the ORF sequence ranged 
from 76.1% to 83.4% (data not shown), a range similar to 
their identities relative to PAK5045.
Phylogenetic analysis with the complete P1 amino acid 
sequences of fully sequenced HPeVs conﬁ  rmed the existence 
of the 6 types deﬁ  ned by previous studies (Figure 1, panel 
A) (15). PAK5045 virus was most similar to HPeV3 strains. 
The identity of P1 amino acid sequences between PAK5045 
virus and both HPeV3 strains analyzed was 77.5%, which 
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Table 1. Nucleotide and amino acid sequence comparisons of HPeV7 candidate prototype PAK5045 with the HPeV prototypes* 
% Nucleotide (amino acid) identity 
Sequence  HPeV1 HPeV2 HPeV3 HPeV4 HPeV5 HPeV6 
5ƍ  UTR  87.6 86.8 95.9 90.2 86.7 89.8 
VP0  71.0 (76.8)  69.6 (75.8)  68.3 (72.3)  69.7 (75.1)  70.1 (75.4)  69.7 (73.7) 
VP3  69.5 (75.3)  69.9 (74.1)  73.2 (83.9)  70.3 (77.5)  69.7 (74.0)  68.8 (74.0) 
VP1  65.8 (69.9)  66.6 (69.5)  68.9 (77.0)  67.8 (68.6)  64.7 (66.4)  63.9 (65.0) 
2A  77.9 (89.3)  75.2 (84.6)  77.5 (85.9)  80.8 (89.3)  80.5 (89.9)  76.5 (85.9) 
2B  80.1 (95.9)  76.8 (95.1)  86.1 (99.2)  83.6 (99.2)  83.6 (97.5)  78.7 (96.7) 
2C  78.9 (91.5)  76.5 (86.6)  83.8 (96.0)  85.9 (97.0)  80.9 (94.5)  79.5 (90.0) 
3A  76.6 (88.0)  76.1 (83.8)  81.8 (94.0)  87.5 (96.6)  78.9 (82.9)  76.1 (89.7) 
3B  73.3 (90.0)  75.0 (90.0)  76.7 (85.0)  85.0 (95.0)  76.7 (90.0)  70.0 (90.0) 
3C  81.3 (98.0)  81.2 (98.0)  83.5 (98.0)  86.3 (98.0)  80.3 (99.0)  83.0 (99.0) 
3D  83.2 (94.9)  82.8 (94.0)  88.7 (96.8)  90.8 (97.2)  83.8 (95.9)  83.6 (95.3) 
3ƍ  UTR  85.1 89.8 95.5 94.4 85.2 83.0 
ORF  76.3 (86.7)  75.6 (84.8)  79.5 (89.1)  80.8 (88.5)  77.0 (86.6)  76.0 (85.4) 
*Sequences for the HPeV prototypes, HPeV1 (Harris, S45208), HPeV2 (Williamson, AJ005695), HPeV3 (A308/99, AB084913), HPeV4 (K251176-02, 
DQ315670), HPeV5 (CT86-6760, AF055846), and HPeV6 (NII561–2000, AB252582), were obtained from GenBank. HPeV, human parechoviruses. 
Figure 1. Phylogenetic analysis of PAK5045 virus (arrows) and parechovirus strains based on A) the complete amino acid sequence of 
P1 region and B) the complete amino acid sequence of viral protein 1 (VP1). All parechovirus sequences were obtained from GenBank, 
including 13 completely sequenced parechoviruses, human parechoviruses (HPeV) 1 Harris (Q66578), HPeV1 BNI-788St (ABK54353), 
HPeV2 Williamson(CAA06679), HPeV3 A308/99(BAC23086), HPeV3 Can82853-01(CAI64373),HPeV4 K251176-02 (ABC41566), HPeV4 
T75-4077 (CAJ84484), HPeV5 CT86-6760 (Q9YID8), HPeV5 T92-15 (CAJ84483),HPeV6 NII561-2000 (BAF63403), HPeV6 2005-823 
(ABX79460), HPeV6 BNI-67/03 (ABS82455), Ljungan virus 87-012 (AAM46079), and 17 sequences with accession numbers shown 
directly on the tree. Both trees were constructed by the neighbor-joining method with 1,000 bootstrap replicates using MEGA4.was lower than some HPeVs intertype amino acid identities 
(e.g., average of 82.4% between HPeV1 and HPeV2, 78.3% 
between HPeV1 and HPeV4, 80.4% between HPeV1 and 
HPeV6, 78.4% between HPeV2 and HPeV6, and 80.5% be-
tween HPeV4 and HPeV5) (data not shown).
Consistent with the P1 amino acid tree, phylogenetic 
analysis with VP1 capsid proteins also showed 6 estab-
lished types (Figure 1, panel B) (5). PAK5045 VP1 was 
slightly closer to type 3 strains, with the greatest amino acid 
identity being 78.8% (Table 2), and more divergent from 
the other established HPeV types. We retrieved from Gen-
Bank, and then analyzed, genetic relationships among 92 
full-length VP1 amino acid sequences and with PAK5045. 
None clustered with PAK5045 as a close genetic lineage. 
The amino acid identities between PAK5045 and HPeV3 
strains ranged from 69.9% to 78.8%, outside the HPeV3 
intratype range of 85.8%–100% (Table 2).
The PAK5045 polyprotein contained 9 putative cleav-
age sites at VP0/VP3 (T/A), VP3/VP1 (Q/N), VP1/2A 
(E/S), 2A/2B (Q/G), 2B/2C (Q/G), 2C/3A (Q/T), 3A/3B 
(E/R), 3B/3C(Q/R), and 3C/3D (Q/G). Alignments showed 
that VP3/VP1, VP1/2A, and 2C/3A cleavage sites differed 
for PAK5045 relative to those of fully sequenced HPeVs 
strains, whereas the other 6 sites were conserved. The 
cleavage site in VP0/VP3 of PAK5045 was identical to 
that of HPeV2 but not to those of other types. The VP1/2A 
cleavage site was identical between PAK5045 and HPeV3 
strains A308/99 and Can82853-01 but not other HPeVs. 
The RGD motif (arginine-glycine-aspartic acid) at the C 
terminus of VP1 was absent in PAK5045 and in HPeV3 
strains A308/99 and Can82853-01, which indicates that 
mechanisms other than RGD binding to integrins may oc-
cur during PAK5045 infection.
To identify recombination events between the differ-
ent HPeV types, we performed SimPlot analysis (http://
sray.med.som.jhmi.edu/SCRoftware/simplot) of the 6 
complete nucleotide HPeV prototype genomes against 
PAK5045 (Figure 2). In general, PAK5045 was closer to 
HPeV3 and HPeV4 than to the other viruses. PAK5045 
showed a relatively higher degree of nucleotide similar-
ity to HPeV3 A308/99 in the P1 region consistent with the 
P1 phylogenetic tree. Downstream of nucleotide position 
3600, HPeV4 K251176-02 became the closest relative of 
PAK5045 in most of the nonstructural (P2/3) region, which 
suggests an ancient recombination event.
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Table 2. VP1 amino acid sequence comparisons of HPeV types* 
Average (range) of VP1 amino acid identities, %
Type  HPeV1 HPeV2 HPeV3 HPeV4 HPeV5 HPeV6 PAK5045
HPeV1 94.7
(81.8–100.0)
78.3
(71.7–80.0)
71.2
(61.9–73.9)
75.6
(69.7–78.4)
72.6
(66.7–74.9)
78.2
(71.9–81.8)
68.1
(64.6–69.9)
HPeV2 99.4
(99.1–100.0)
71.4
(65.5–72.6)
74.9
(74.3–76.1)
71.8
(70.4–72.6)
73.7
(73.5–73.9)
69.5
(–)
HPeV3 97.3
(85.8–100.0)
70.8
(66.4–71.7)
66.8
(60.6–68.6)
73.9
(66.8–75.7)
77.6
(69.9–78.8)
HPeV4 97.0
(96.6–97.8)
78.3
(75.9–80.2)
72.8
(72.3–73.2)
68.4
(68.1–68.6)
HPeV5 96.9
(94.8–100.0)
72.0
(71.0–72.7)
66.1
(65.5–66.4)
HPeV6 97.2
(95.7–98.7)
64.9
(64.6–65.0)
PAK5045 –
*92 full-length VP1 amino acid sequences were obtained from GenBank, including 46 HPeV1, 4 HPeV2, 31 HPeV3, 3 HPeV4, 4 HPeV5, and 4 HPeV 6 
VP1 amino acid sequences. The accession nos. are AAA72291, AAB32466, AAB23363, AAC79756, ABC41566, ABK54353, ABS82455, ABS82457–
82462, ABX79460, ABX79453, BAC23086, BAD05057–05062, BAF63403, BAF76536–76596, CAA06679, CAI64373, CAJ84483–84484, NP_046804, 
NP_740386, Q66578, and Q9YID8. HPeV, human parechoviruses; VP1, viral protein 1.  
Figure 2. SimPlot (http://sray.med.som.jhmi.edu/SCRoftware/
simplot) analysis of the full-length sequences of the human 
parechovirus (HPeV) prototypes against PAK5045 query, based on 
nucleotide similarities. Each curve compares the PAK5045 genome 
with an HPeV prototype. The Kimura 2-parameter model was 
applied with a transition/transversion (Ts/Tv) ratio of 3.0 (5), and a 
sliding window of 600 nt with a step size of 10 nt was used.Novel Human Parechovirus Type
Conclusions
We identiﬁ  ed and characterized a novel HPeV type 
from the stool sample of a healthy child who had been in 
close contact with a person who had nonpolio AFP. The 
genome sequence diverged sufﬁ  ciently from the 6 known 
HPeVs to qualify as a candidate for the prototype of HPeV7. 
Using only a low-level shotgun sequencing method, we de-
tected HPeVs in 9% (6/65) of stool samples from patients 
with nonpolio AFP, including HPeV types 1, 5, 6, and 
7. A more sensitive method, such as HPeV-directed RT-
nested PCR, is likely to have detected a higher prevalence. 
The median age of sampled patients was 3 years (range 1 
month–15 years), and all HPeV-positive patients were <3 
years of age.
In a previous study, HPeVs were isolated from 0.3% 
of 13,656 various clinical samples collected in Japan (14 
HPeV1, 16 HPeV3, 10 HPeV6, and 1 HPeV4) (6). In Ger-
many, the detection rate of HPeVs did not differ signiﬁ  -
cantly between patients with acute diarrhea and controls, 
with 11.6% (7/60) of children <2 years of age being HPeV 
positive (15). In a Dutch study of 303 isolates showing cy-
topathic effects consistent with enterovirus infection, 12% 
were HPeV positive, with 27 HPeV1 and 10 HPeV3, all 
in children <3 years of age (7). HPeV infection, therefore, 
seems to be associated with young children (<3 years). 
More studies are needed to associate HPeV infection (with 
any genotypes) with development of neurologic disease, 
such as AFP.
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